Division of BridgeBio Pharma Inc.
Latest From PellePharm Inc.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- BridgeBio Pharma Inc.
- Senior Management
Sanuj K Ravindran, MD, Pres. & CEO
Ervin Epstein, MD, Dir. & CMO
Gerd Kochendoerfer, PhD, SVP, Head of Operations
Alix Alderman, VP, Reg. Affairs
David HInds, VP, Clinical Operations
- Contact Info
101 Mission St.
San Francisco, CA 94105
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.